COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review
Abstract Coronavirus disease-2019 (COVID-19), a viral respiratory illness caused by the
severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), may predispose patients …
severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), may predispose patients …
Hematological findings and complications of COVID‐19
E Terpos, I Ntanasis‐Stathopoulos… - American journal of …, 2020 - Wiley Online Library
COVID‐19 is a systemic infection with a significant impact on the hematopoietic system and
hemostasis. Lymphopenia may be considered as a cardinal laboratory finding, with …
hemostasis. Lymphopenia may be considered as a cardinal laboratory finding, with …
Scientific and standardization committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized …
2 METHODS This guidance statement is a collaborative effort of the Perioperative and
Critical Care Thrombosis and Haemostasis Subcommittee, along with members of the …
Critical Care Thrombosis and Haemostasis Subcommittee, along with members of the …
Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report
Background Emerging evidence shows that severe coronavirus disease 2019 (COVID-19)
can be complicated by a significant coagulopathy, that likely manifests in the form of both …
can be complicated by a significant coagulopathy, that likely manifests in the form of both …
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of …
Abstract Background: COVID-19–related acute illness is associated with an increased risk of
venous thromboembolism (VTE). Objective: These evidence-based guidelines from the …
venous thromboembolism (VTE). Objective: These evidence-based guidelines from the …
Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry
D Giannis, SL Allen, J Tsang, S Flint… - Blood, The Journal …, 2021 - ashpublications.org
Thromboembolic events, including venous thromboembolism (VTE) and arterial
thromboembolism (ATE), and mortality from subclinical thrombotic events occur frequently in …
thromboembolism (ATE), and mortality from subclinical thrombotic events occur frequently in …
Diagnostic value of D-dimer in COVID-19: a meta-analysis and meta-regression
H Zhan, H Chen, C Liu, L Cheng… - Clinical and Applied …, 2021 - journals.sagepub.com
The prognostic role of hypercoagulability in COVID-19 patients is ambiguous. D-dimer, may
be regarded as a global marker of hemostasis activation in COVID-19. Our study was to …
be regarded as a global marker of hemostasis activation in COVID-19. Our study was to …
Prevention of venous thromboembolism in 2020 and beyond
Venous thromboembolism (VTE) is the third most common cause of vascular mortality
worldwide and comprises deep-vein thrombosis (DVT) and pulmonary embolism (PE). In …
worldwide and comprises deep-vein thrombosis (DVT) and pulmonary embolism (PE). In …
Elevated D-dimer levels are associated with increased risk of mortality in coronavirus disease 2019: a systematic review and meta-analysis
The 2019 novel coronavirus, declared a pandemic, has infected 2.6 million people as of
April 27, 2020, and has resulted in the death of 181,938 people. d-dimer is an important …
April 27, 2020, and has resulted in the death of 181,938 people. d-dimer is an important …
Venous thromboembolism among hospitalized patients with COVID-19 undergoing thromboprophylaxis: a systematic review and meta-analysis
Background: Preliminary evidence indicates that prophylactic-dose thromboprophylaxis may
be inadequate to control the increased risk of venous thromboembolism (VTE) in patients …
be inadequate to control the increased risk of venous thromboembolism (VTE) in patients …